Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People scheduled at Mayo Clinic Rochester to receive a treatment called 177Lu PSMA-617 (a type of radioligand therapy for prostate cancer)
• People who have been diagnosed with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy, where a specific type of scan (PSMA PET scan) shows a score of 2 or higher on the Mayo PET report
• People willing to provide blood samples for research purposes (this requirement may be waived in certain situations — confirm with trial site)
• People who are willing and able to sign a consent form agreeing to take part
• People who are able to complete questionnaires, either on their own or with help
• People who are willing to return to the enrolling clinic for follow-up visits during the study
• For a later stage of the trial (randomisation), people whose scans after treatment cycles 2 through 5 show a near-complete response, meaning almost no detectable cancer activity on the follow-up scan
• For randomisation, people who have no serious side effects that would require their next treatment dose to be delayed or reduced
• For randomisation, people whose blood counts and kidney and liver function fall within the ranges required by the trial (confirm specific values with trial site)

Who may not be able to join:

• People who have another active cancer that currently requires treatment such as radiation, chemotherapy, or immunotherapy
• People who are currently taking part in another clinical trial that involves a treatment for their prostate cancer
• People who have not fully recovered from serious side effects of a previous treatment (with a possible exception for mild, stable nerve-related sensory issues lasting at least 3 months — confirm with trial site)
• People with ongoing or active infections, or other uncontrolled illnesses, including certain mental health or social situations that could affect participation
• People who need continuous oxygen therapy due to breathing difficulties caused by their cancer or another condition
• People who are capable of fathering a child and are unwilling to use adequate contraception during the trial, given that the effects of the investigational treatment on a developing baby are not known
• People with other serious ongoing health conditions that, in the treating doctor's judgement, would make participation unsafe or affect how the trial results are assessed
• People who have had a heart attack within the past 6 months, or who have heart failure requiring ongoing treatment for dangerous heart rhythm problems
• People who have experienced a serious harmful side effect (relevant to a later re-registration stage of the trial)

Important: Always verify eligibility with the trial site directly before applying.